J&J sales
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer & Specialty Pharmaceuticals "will maintain a limited number of products containing pseudoephedrine for behind the counter sale" but "is in the process of reformulating our products that contain this ingredient," J&J VP- Investor Relations Helen Short stated during a third-quarter earnings call Oct. 18. The "negative impact" of restrictions implemented on products containing pseudoephedrine was responsible for offsetting sales growth for the McNeil division during the third quarter, Short added. The McNeil franchise had operational growth of 11% for the third quarter, six points of which were a result of a reclassification of certain OTC products from the pharmaceutical division to McNeil in January, Short said. Imodium, Pepcid and Motilium were among those reclassified (1"The Tan Sheet" July 25, 2005, p. 10). Global consumer sales of $2.2 bil. for the quarter represented an increase of 10.2% over the prior-year period, the firm said...
You may also be interested in...
McNeil Sales Still Slowed By Pseudoephedrine Limits
Pseudoephedrine restrictions were the primary driver behind a 7% decline in first-quarter U.S. sales for Johnson & Johnson's McNeil Consumer division, J&J reported during an April 18 earnings call
Perrigo’s Full Range Of Pseudoephedrine Stand-Ins Must Wait For Next Year
Perrigo will not have a complete phenylephrine portfolio available to replace pseudoephedrine products until next year's cough/cold season, the company said during a fiscal 2006 first-quarter earnings call
McNeil Product Reclassification Accounts For 50% International Sales Gain
McNeil's international OTC drug and nutritional sales rose 50% on a reported basis in the second quarter, reflecting the addition of a number of OTCs that were previously part of parent J&J's pharmaceutical group